Feng Runtao, Zhong Bingzhou, Liang Haoxin, Chen Jianan, Hu Jianmin, Zhou Song, Liao Guorong, Liao Jun, Jiang Weiwei, Yang Siqiang, Liu Yongguang
Department of Organ transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Ren Fail. 2025 Dec;47(1):2562446. doi: 10.1080/0886022X.2025.2562446. Epub 2025 Sep 18.
The use of kidneys from small pediatric donors (< 5 years) for single kidney transplantation (SKT) may expand the donor pool. In recent years, many national allocation policies have given priority to pediatric recipients. However, comparative studies involving pediatric and adult recipients of single kidney transplants from small pediatric donors are limited. All patients who underwent SKT from small pediatric donors aged < 5 years at our center between January 1, 2015 and June 30, 2024 were included in this study. The outcomes included graft survival, patient survival, and post-transplant complications, which were compared between pediatric and adult recipients. The patient cohort included 83 adult recipients and 55 pediatric recipients from 48 and 40 small pediatric donors (aged < 5 years), respectively. Three-year death-censored graft survival and patient survival in pediatric recipients were 81.7% and 100%, respectively, which were not significantly different from those in adult recipients (89.0% and 95.8%). The leading cause of graft loss was vascular thrombosis (6 cases), followed by rejection (5 cases). No significant differences were observed between pediatric and adult recipients regarding primary nonfunction, the incidence of proteinuria, vascular and urinary complications, or the cumulative incidence of acute rejection. However, adult recipients experienced a significantly higher incidence of delayed graft function than pediatric recipients. SKT from small pediatric donors achieved comparable outcomes in adult and pediatric recipients, validating that current policies prioritizing pediatric recipients are clinically appropriate. Addressing risks of vascular thrombosis and rejection may further improve outcomes.
使用来自小儿小供体(<5岁)的肾脏进行单肾移植(SKT)可能会扩大供体库。近年来,许多国家分配政策都优先考虑小儿受者。然而,涉及小儿小供体单肾移植的小儿与成人受者的比较研究有限。本研究纳入了2015年1月1日至2024年6月30日期间在我们中心接受来自年龄<5岁的小儿小供体的SKT的所有患者。比较了小儿和成人受者的移植肾存活、患者存活及移植后并发症等结局。患者队列包括分别来自48例和40例小儿小供体(年龄<5岁)的83例成人受者和55例小儿受者。小儿受者的3年死亡截尾移植肾存活率和患者存活率分别为81.7%和100%,与成人受者(89.0%和95.8%)无显著差异。移植肾丢失的主要原因是血管血栓形成(6例),其次是排斥反应(5例)。在原发性无功能、蛋白尿发生率、血管和泌尿系统并发症或急性排斥反应的累积发生率方面,小儿和成人受者之间未观察到显著差异。然而,成人受者延迟移植肾功能的发生率明显高于小儿受者。来自小儿小供体的SKT在成人和小儿受者中取得了可比的结局,证实了当前优先考虑小儿受者的政策在临床上是合适的。解决血管血栓形成和排斥反应的风险可能会进一步改善结局。